Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), has emerged as a significant focus in clinical research due to its increasing prevalence and potential for severe liver complications. As a clinical trial company, we are at the forefront of researching innovative treatments for this complex condition.